Association of Alanine Aminotransferase Flares to Hepatitis B Surface Decline During Tenofovir Alone or With Pegylated Interferon Alfa-Reference-Cited by-全球学者库

Association of Alanine Aminotransferase Flares to Hepatitis B Surface Decline During Tenofovir Alone or With Pegylated Interferon Alfa

Published:2023-06-13 Issue:11 Volume:118 Page:2075-2079
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Perrillo Robert¹,Lok Anna S.²,Leonard Kelsey³,Ghany Marc G.⁴,Terrault Norah⁵,Belle Steven H.⁶,Janssen Harry L.A.⁷,

Affiliation:

1. Baylor Scott and White Medical Center, Dallas, Texas, USA;

2. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA;

3. Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA;

4. Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA;

5. Gastrointestinal and Liver Diseases Division, Keck School of Medicine, University of Southern California, Los Angeles, California, USA;

6. Departments of Epidemiology and Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA;

7. Toronto Centre for Liver Diseases, University Health Network, Toronto, Ontario, Canada.

Abstract

INTRODUCTION: We aimed to determine whether the intensity of alanine aminotransferase (ALT) flares during antiviral therapy is associated with the level of hepatitis B surface antigen (HBsAg) decline. METHODS: Quantitative HBsAg was determined during tenofovir monotherapy or tenofovir plus peginterferon alfa-2a in 201 participants with hepatitis B e antigen–positive or –negative chronic hepatitis B. A multivariable analysis identified factors associated with a shorter time to reduction in HBsAg. RESULTS: Fifty flares occurred during treatment of which 74% were moderate (ALT >5–10 × upper limit of normal) or severe (ALT >10 × upper limit of normal). These flares were associated with greater HBsAg decline compared with no flares. Significantly faster times to HBsAg decline >1 log10 IU (P = 0.04) and to HBsAg level <100 IU/mL (P = 0.01) were observed with severe flares. DISCUSSIONS: Flare severity is a potentially important factor associated with shorter time to HBsAg reduction. These findings can be useful when evaluating HBsAg response to evolving hepatitis B virus therapies.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference14 articles.

1. Serum aminotransferase flares in chronic hepatitis B infection: The good and the bad;Ghany;Lancet,2020

2. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease;Perrillo;Gastroenterology,2001

3. Association between serum alanine aminotransferase flares and hepatitis B antigen seroconversion and HBV DNA decrease in untreated patients with chronic HBV infection;Brahmania;Clin Gastroenterol Hepatol,2019

4. Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management;Chang;J Hepatol,2014

5. Treatment and HBeAg-status differentiate clinical outcomes following ALT flares—Analysis of tenofovir disoproxil fumarate (TDF) plus peginterferon (PEG) combination study for chronic hepatitis B (CHB);Chan;Hepatology,2015